DMC promotes HBV-related HCC immune microenvironment, which not only enrich the relationship between inflammatory factors (mPGES-1/PGE2 pathway) and the immunosuppression programmed death-ligand 1 (PD-L1), but also provide an important strategic reference for multitarget or combined immunotherapy of HBV-related HCC. Here, CD274 is linked to hepatocellular carcinoma.